To better understand the role of NHE1 in the progression of glioma, we compared the overall survival time of glioma patients between the group with high and low NHE1 (SLC9A1) mRNA expression in the GSE16011 cohort. This evidence concerns the gene SLC9A1 and central nervous system cancer.